1
|
Vahedi E, Ghanei M, Ghazvini A, Azadi H, Izadi M, Panahi Y, Fathi S, Salesi M, Saadat SH, Ghazale AH, Rezapour M, Mozafari A, Zand N, Parsaei MR, Ranjkesh MH, Jafari R, Movaseghi F, Darabi E. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. Daru 2020; 28:507-516. [PMID: 32562159 PMCID: PMC7303568 DOI: 10.1007/s40199-020-00353-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 06/02/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19). METHODS This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir. RESULTS The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001). CONCLUSION This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.
Collapse
Affiliation(s)
- Ensieh Vahedi
- Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Mostafa Ghanei
- Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
| | - Ali Ghazvini
- Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Hossein Azadi
- Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Morteza Izadi
- Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Yunes Panahi
- Faculty of pharmacy, pharmacotherapy department, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | | | - Mahmood Salesi
- Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Seyed Hassan Saadat
- Behavioral sciences research center, Lifestyle institute, Baqiatallah University of Medical Sciences, Tehran, Iran
| | - Amir Hossein Ghazale
- Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran
| | - Mohammad Rezapour
- Student Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran
| | - Abolfazl Mozafari
- Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran
| | - Nahid Zand
- Department of Internal Medicine, Qom university of medical sciences, Qom, Iran
| | | | | | - Ramezan Jafari
- Department of Radiology and Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Fatemeh Movaseghi
- Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran
| | - Enayat Darabi
- School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Zand N, Najafi S, Mansouri P, Fateh M, Fashtami LA, Djavid GE, Aghazadeh A. 372 NACLT (Non-ablative CO2 laser 10600 nm therapy): a new approach to relieve pain in mild to moderate oral mucositis following breast cancer chemotherapy (a pilot study). European Journal of Cancer Supplements 2010. [DOI: 10.1016/s1359-6349(10)70398-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|